Potential Cytochrome P450 (CYP) Drug Interactions



List of drugs that may have potential CYP1A2 interactions

CYP1A2 Substrates

|Acenocoumarol |Duloxetine |Estropipate |Ropinirole |

|Aminophylline |Estradiol |Flutamide |Tacrine |

|Betaxolol |Estrogens, conjugated |Fluvoxamine |Theophylline |

|Caffeine |(synthetic) |Guanabenz |Thiothixene |

|Clomipramine |Estrogens, conjugated |Mexiletine |Trifluoroperazine |

|Clozapine |(equine) |Mirtazapine | |

|Cyclobenzaprine |Estrogens, conjugated |Pimozide | |

|Dacarbazine |(esterified) |Propanolol | |

|Doxepin |Estrone |Riluzole | |

CYP 1A2 Inhibitors

|Albendazole |Erythromycin |Methimazole |Propafenone |

|Alosetron |Estradiol |Methoxsalen |Propofol |

|Amiodarone |Estrogens, conjugated |Mexiletine |Propanolol |

|Amitriptyline |(synthetic) |Miconazole |Ranitidine |

|Amlodipine |Estrogens, conjugated |Mirtazapine |Rofecoxib |

|Anastrozole |(equine) |Moclobemide |Ropinirole |

|Atazanavir |Ethinyl estradiol |Modafinil |Selegiline |

|Bortezomib |Fluconazole |Nalidixic acid |Sertraline |

|Bromocriptine |Fluoxetine |Nefazodone |Sildenafil |

|Buprenorphine |Fluphenazine |Nelfinavir |Sulconazole |

|Caffeine |Flutamide |Nevirapine |Tacrine |

|Cimetidine |Fluvastatin |Nifedipine |Tenofovir |

|Ciprofloxacin |Fluvoxamine |Nisoldipine |Theophylline |

|Citalopram |Gemfibrozil |Norfloxacin |Thiabendazole |

|Clarithromycin |Ginseng (2) |Ofloxacin |Thioridazine |

|Clotrimazole |Imipramine |Olanzapine |Ticlopidine |

|Clozapine |Interferon-α2a |Omeprazole |Tioconazole |

|Delavirdine |Interferon-α2b |Ondansetron |Tocainide |

|Dexmedetomidine |Interferon-γ1b |Orphenadrine |Tranylcypromine |

|Diclofenac |Isoniazid |Paroxetine |Verapamil |

|Disulfiram |Ketoconazole |Peginterferon-α2a |Zafirlukast |

|Drospirenone |Lidocaine |Peginterferon-α2b |Zileuton |

|Echinacea (1) |Lomefloxacin |Pentoxifylline | |

|Enoxacin |Losartan |Perphenazine | |

|Entacapone |Mestranol |Primaquine | |

CYP1A2 Inducers

|Aminoglutethimide |Phenobarbital |Primidone |Rifampin |

|Carbamazepine | | | |

When drugs classified as ‘substrates’ are co-administered with (Study Agent), there is the potential for higher concentrations of the ‘substrate’. When (Study Agent) is co-administered with compounds classified as ‘inhibitors’, increased plasma concentrations of (Study Agent) is the potential outcome. The co-administration of ‘inducers’ would potentially lower plasma (Study Agent) concentrations.

Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 15TH ed. Hudson, OH; LexiComp Inc. 2007: 1899-1912.

Only major substrates and effective inducers are listed.

Additional information for drug interactions with cytochrome P450 isoenzymes can be found at .

(1) Gorski, et al. (2004). Clin Pharmacol Ther. 75:89-100.

(2) Saruwatari, et al. (2003). J Pharm Pharmacol. 55:1553-1559.

Updated on May 1, 2007

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download